Dr. Lynce on Remaining Questions With PARP Inhibitors in Breast Cancer
Filipa Lynce, MD, discusses remaining questions regarding the use of PARP inhibitors in breast cancer.
Dr. Lynce on FDA Approval of Atezolizumab/Nab-Paclitaxel in TNBC
Filipa Lynce, MD, discusses the FDA approval of atezolizumab plus nab-paclitaxel for the frontline treatment of patients with unresectable locally advanced or metastatic PD-L1
How To Get the Most out of Your Fellowship
Only by the end of my first year of fellowship did I realize that beyond your fellowship experience there is a lot you can gain.
Later-Line Ruxolitinib Use Produces Ongoing Benefit in Real-World Patients With cGVHD
Orca-T Data With Survival, Tolerability Extends to Older Patients With Hematologic Cancers
Dr Ramdial on Gemcitabine/Clofarabine/Busulfan for Lymphoma Stem Cell Transplant
Retrospective Analysis Shows Post-HCT Survival Benefits With Orca-T Vs PTCy in Hematologic Malignancies
2 Commerce Drive Cranbury, NJ 08512